CleveX Inc. is a medical device company that is developing and marketing skin biopsy closure and repair solutions for the dermatology cosmetic surgery and primary care physicians. CleveX (LLC) started out in 2004 as a joint venture between Cleveland Clinic Foundation (Cleveland OH) and IDx Medical Design (Cincinnati OH) to develop and commercialize surgical dermatology and skin repair innovations generated by leading physicians at the Cleveland Clinic. The company's lead technology platform is the ExiClip. The ExiClip is a single-step disposable surgical device that efficiently excises a skin lesion while simultaneously closing and repairing the surgical site.
CleveX Frequently Asked Questions (FAQ)
When was CleveX founded?
CleveX was founded in 2003.
Where is CleveX's headquarters?
CleveX's headquarters is located at 1275 Kinnear Road, Columbus.
What is CleveX's latest funding round?
CleveX's latest funding round is Unattributed VC.
How much did CleveX raise?
CleveX raised a total of $3.5M.
Who are the investors of CleveX?
Investors of CleveX include Plymouth Growth Partners, Reservoir Venture Partners, Ohio TechAngels and Rev1 Ventures.
Who are CleveX's competitors?
Competitors of CleveX include InterRad Medical, OrthAlign, Cohera Medical, SciBase, Small Bone Innovations, MAKO Surgical, ENTrigue Surgical, Caliber Imaging & Diagnostics, Kfx Medical, nFocus Neuromedical and 12 more.
Compare CleveX to Competitors
CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
Primaeva Medical is an early stage medical device company developing a skin tightening and rejuvenation dermatological device
InterRad Medical is developing a catheter anchoring device called SecurAcath Catheter Retention System. The SecurAcath System is a new and method for holding catheters in place over and extended time. The SecurAcath System aims to utilize a very small anchor that deploys just under the skin to hold a catheter securely in place.
CCS is developing a device to aid colostomy patients in managing their stomas (formerly Uniseed investee Colocare) and a surgical procedure for urinary incontinence based on electrical stimulation of smooth muscle grafts. Both technologies are currently under clinical evaluation.
OrthAlign provides orthopedic surgeons with user-friendly and cost-effect technology for precise alignment.